miRNA-206在胃间质瘤组织中的表达及其临床意义

doi:10.6040/j.issn.1671-7554.0.2015.172

摘要/Abstract

摘要： 目的探讨miRNA-206在胃间质瘤中的表达及意义。方法收集胃间质瘤治疗后的切除标本,采用qRT-PCR方法检测53例胃间质瘤及对应正常胃组织中miRNA-206的表达,并分析其与临床病理因素的关系。结果胃间质瘤组织中miRNA-206表达显著低于对应正常胃组织(P<0.05),且核分裂数 ≥ 5/50 HPF病例的miRNA-206表达显著低于核分裂数<5/50 HPF病例的miRNA-206表达(P<0.05), Fletcher分级中/高危病例的miRNA-206表达显著低于极低/低危分级病例的miRNA-206表达(P<0.05)。结论 miRNA-206在胃间质瘤组织中表达下调,且与核分裂像及Fletcher分级密切相关,提示其在胃间质瘤的发生发展过程中发挥重要作用。

关键词: 胃间质肿瘤, miRNA-206, 核分裂像, 临床特征, Fletcher分级

Abstract: Objective To evaluate the expression and significance of miRNA-206 in the development of gastric stromal tumor. Methods Fifty-three cases of the surgical specimens of gastric stromal tumor were collected. miRNA-206 levels in matched pairs of gastric stromal tumor and normal adjacent tissue samples were examined using qRT-PCR; the relationship between miRNA-206 levels and clinical characteristics were investigated. Results Expression of miRNA-206 was significantly lower in tumor than that in adjacent normal tissues (P<0.05). Expression of miRNA-206 in cases with mitotic count ≥ 5/50HPF was significantly lower than that with mitotic count<5/50HPF (P<0.05). By Fletcher risk stratification system, expression of miRNA-206 in intermediate/high-risk cases was significantly lower than that in very low/low risk cases (P<0.05). Conclusion In gastric stromal tumor, miRNA-206 expression is significantly down-regulated, and is closely associated with mitotic counts and Fletcher risk stratification system, which suggests that miRNA-206 play an important role in the process of development of gastric stromal tumor.

Key words: Gastric stromal tumors, Clinical characteristics, miRNA-206, Mitotic count, Fletcher risk stratification

中图分类号:

R573

姚冬雪, 赵琪, 秦成勇. miRNA-206在胃间质瘤组织中的表达及其临床意义[J]. 山东大学学报（医学版）, 2015, 53(12): 67-70.

YAO Dongxue, ZHAO Qi, QIN Chengyong. Clinical significance of miRNA-206 expression in gastric stromal tumor[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(12): 67-70.

参考文献

[1] Shinomura Y, Kinoshita K, Tsutsui S, et al. Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors[J]. J Gastroenterol, 2005, 40(8):775-780.
[2] Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors[J]. J Clin Oncol, 2004, 22(18):3813-3825.
[3] He L, Hannon GJ. MicroRNAs:small RNAs with a big role in gene regulation[J]. Nat Rev Genet, 2004, 5(7):522-531.
[4] Croce CM. Causes and consequences of microRNA dysregulation in cancer[J]. Nat Rev Genet, 2009, 10(10):704-714.
[5] Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors:a consensus approach[J]. Int J Surg Pathol, 2002, 10(2):81-89.
[6] Miettinen M, Lasota J. Gastrointestinal stromal tumors:review on morphology, molecular pathology, prognosis, and differential diagnosis[J]. Arch Pathol Lab Med, 2006, 130(10):1466-1478.
[7] Lennartsson J, Ronnstrand L. The stem cell factor receptor/c-Kit as a drug target in cancer[J]. Curr Cancer Drug Targets, 2006, 6(1):65-75.
[8] Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors:a consensus approach[J]. Hum Pathol, 2002, 33(5):459-465.
[9] Subramanian S, Lui WO, Lee CH, et al. MicroRNA expression signature of human sarcomas[J]. Oncogene, 2008, 27(14):2015-2026.
[10] Jovanovic M, Hengartner MO. miRNAs and apoptosis:RNAs to die for[J]. Oncogene, 2006, 25(46):6176-6187.
[11] Fabian MR, Sonenberg N. The mechanics of miRNA-mediated gene silencing:a look under the hood of miRISC[J]. Nat Struct Mol Biol, 2012, 19(6):586-593.
[12] Wang X, Ling C, Bai Y, et al. MicroRNA-206 is associated with invasion and metastasis of lung cancer[J]. Anat Rec (Hoboken), 2011, 294(1):88-92.
[13] Zhang L, Liu X, Jin H, et al. miR-206 inhibits gastric cancer proliferation in part by repressing cyclinD2[J]. Cancer Lett, 2013, 332(1):94-101.
[14] Li Y, Hong F, Yu Z. Decreased expression of microRNA-206 in breast cancer and its association with disease characteristics and patient survival[J]. J Int Med Res, 2013, 41(3):596-602.
[15] Zhou J, Tian Y, Li J, et al. miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2[J]. Biochem Biophys Res Commu, 2013, 433(2):207-212.
[16] Zhang T, Liu M, Wang C, et al. Down-regulation of MiR-206 promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression[J]. Anticancer Res, 2011, 31(11):3859-3863.
[17] Taulli R, Bersani F, Foglizzo V, et al. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation[J]. J Clin Invest, 2009, 119(8):2366-2378.
[18] Liu W, Xu C, Wan H, et al. MicroRNA-206 overexpression promotes apoptosis, induces cell cycle arrest and inhibits the migration of human hepatocellular carcinoma HepG2 cells[J]. Int J Mol Med, 2014, 34(2):420-428.
[19] Bao YP, Yi Y, Peng LL, et al. Roles of microRNA-206 in osteosarcoma pathogenesis and progression[J]. Asian Pac J Cancer Prev, 2013, 14(6):3751-3755.
[20] Haller F, von Heydebreck A, Zhang JD, et al. Localization-and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31[J]. J Pathol, 2010, 220(1):71-86.
[21] Yamamoto H, Kohashi K, Fujita A, et al. Fascin-1 overexpression and miR-133b downregulation in the progression of gastrointestinal stromal tumor[J]. Mod Pathol, 2013, 26(4):563-571.
[22] Niinuma T, Suzuki H, Nojima M, et al. Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors[J]. Cancer Res, 2012, 72(5):1126-1136.
[23] 刘志,韩少良,黄颖鹏,等.miR-143和miR-145在胃间质瘤组织中的表达及其意义[J].中华普通外科杂志, 2010, 25(8):678-680. LIU Zhi, HAN Shaoliang, HUANG Yingpeng, et al. Clinical significance of miR-143 and miR-145 expression in gastric gastrointestinal stromal tumor[J]. Chin J Gen Surg, 2010, 25(8):678-680.
[24] Liu S, Cui J, Liao G, et al. MiR-137 regulates epithelial-mesenchymal transition in gastrointestinal stromal tumor[J]. Tumour Biol, 2014, 35(9):9131-9138.

相关文章 15

[1]	孔亮博,夏瑞红,赵玉英,王淑贞,王胜军. 齿状核红核苍白球路易体萎缩的临床特征[J]. 山东大学学报 (医学版), 2023, 61(10): 51-57.
[2]	巩雨,高震,王虎清,杨晶雯,张桂莲,展淑琴,张茹,吴海琴. 4例继发性肥大性下橄榄核变性的临床及影像学特点[J]. 山东大学学报 (医学版), 2022, 60(5): 37-42.
[3]	梁子婷,许长娟,曾荣,张锦涛,曾庆师,董亮. 9例儿童异基因造血干细胞移植后闭塞性细支气管炎综合征的临床特征[J]. 山东大学学报 (医学版), 2022, 60(12): 58-62.
[4]	苏丽,曹亚文,刘耀敏,张国民,张建华,崔凤梅. 67例血培养阳性成人布鲁菌感染者的临床特征[J]. 山东大学学报 (医学版), 2022, 60(12): 94-100.
[5]	游雪婷,田兴松. 3 514例乳腺癌9年间临床及病理学特征分析[J]. 山东大学学报 (医学版), 2021, 59(1): 49-54.
[6]	李杨, 王中素, 刘鲁祁, 刘天起, 王东, 柳雪, 王明华, 侯应龙. 某三甲医院80例感染性心内膜炎患者临床特征及内外科疗效比较[J]. 山东大学学报 (医学版), 2020, 58(6): 22-27.
[7]	曹爱华,段春红,邱丙平,路苓,李可亮, 刘学工,周志远,孙建华,鞠秀丽. 山东省儿童新型冠状病毒感染者流行病学及临床特征[J]. 山东大学学报 (医学版), 2020, 58(6): 34-40.
[8]	雷宇,陆婧,顾佳颖,周登峰,李园园,卢桥发. 新型冠状病毒肺炎51例临床特征[J]. 山东大学学报 (医学版), 2020, 58(4): 65-70.
[9]	周生余,王春亭,张伟,王锡明,董亮. 山东省新型冠状病毒肺炎患者537例临床特征与救治效果[J]. 山东大学学报 (医学版), 2020, 58(3): 44-51.
[10]	崔亮亮,耿兴义,赵小冬,杨国樑,常彩云,赵梦娇,李战,王春荣,刘岚铮,阮师漫. 济南市现阶段新型冠状病毒肺炎的流行特征与思考[J]. 山东大学学报 (医学版), 2020, 58(3): 52-57.
[11]	张孝国,马艳,肖嘉安,张忠法. 济南市儿童新型冠状病毒肺炎的临床特征[J]. 山东大学学报 (医学版), 2020, 58(3): 62-64.
[12]	苗萌,贾国勇,刘颖,王翠兰. 36例成人流行性乙型脑炎临床分析和影像学特点[J]. 山东大学学报 (医学版), 2018, 56(2): 23-27.
[13]	李劳冬,明莫瑜,蒋连强,蒋清柏,凌宙贵,吴昕. 气管血管球瘤1例并文献复习[J]. 山东大学学报 (医学版), 2018, 56(12): 111-113.
[14]	聂思月,王震,孙靖宇,刘杰,李娟,魏小娟,路春晓,吕兴龑,王淑云,孙玉萍. ANGPTL5在人胃癌组织中的表达及临床意义[J]. 山东大学学报（医学版）, 2017, 55(8): 61-65.
[15]	王光杰,俎树禄,张秀琳,徐祗顺,周春文,刘玉强,王绍勇. Von-Hippel-Lindau病并发肾癌2例[J]. 山东大学学报（医学版）, 2016, 54(2): 86-89.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed